Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
1,174.80
-25.70 (-2.14%)
Apr 25, 2025, 3:30 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 83.59B INR in the quarter ending December 31, 2024, with 15.85% growth. This brings the company's revenue in the last twelve months to 311.31B, up 14.74% year-over-year. In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of 279.16B with 13.54% growth.
Revenue (ttm)
311.31B
Revenue Growth
+14.74%
P/S Ratio
3.22
Revenue / Employee
11.51M
Employees
27,048
Market Cap
1,000.99B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Dr. Reddy's Laboratories News
- 1 day ago - Nifty 50 top gainers today, April 24: IndusInd Bank, UltraTech Cement, Grasim Industries, Dr. Reddy’s and more - Business Upturn
- 10 days ago - Dr Reddy’s shares jump over 2% as Nuvama reiterates ‘Buy’ with Rs 1,533 target; company denies layoff report - Business Upturn
- 10 days ago - Pharma co Dr Reddy's to reduce costs - The Times of India
- 11 days ago - 'Factually incorrect': Dr. Reddy clears air amid workforce reduction rumors - The Times of India
- 11 days ago - Dr. Reddy’s denies report of 25% workforce cost cut amid Revlimid margin strain - Business Upturn
- 11 days ago - Dr Reddy’s initiates 25% workforce reduction, report suggests - Seeking Alpha
- 15 days ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 16 days ago - Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’ - Business Upturn